T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy - Wikidata - wikimedia - TriplyDB

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

http://www.wikidata.org/entity/Q36799229

about

Evolution of the immune system in humans from infancy to old age Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy Targeting the tumor vasculature to enhance T cell activity Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells Structural Model of the Extracellular Assembly of the TCR-CD3 Complex.Recent advances in T-cell engineering for use in immunotherapy TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.Highly functional T-cell receptor repertoires are abundant in stem memory T cells and highly shared among individuals.T cell avidity and tumor immunity: problems and solutions Specific increase in potency via structure-based design of a TCR.Engineering improved T cell receptors using an alanine-scan guided T cell display selection system Reassessing target antigens for adoptive T-cell therapy.T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8 Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.New development in CAR-T cell therapy.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Molecular insights for optimizing T cell receptor specificity against cancer.Mitigating the toxic effects of anticancer immunotherapy.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions.New approaches for the immunotherapy of acute myeloid leukemia.Is autoimmunity the Achilles' heel of cancer immunotherapy?A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis.Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.Tumor-targeting domains for chimeric antigen receptor T cells.The Principles of Engineering Immune Cells to Treat Cancer.Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells.

P2860

Q26772107-77C5C528-DCDA-4B96-A423-3D32F9874F25 Q26774669-63316CAF-AAE9-4A76-81D9-F7EB4513D289 Q26781296-226B7B32-8936-4687-B62F-A6FBB179091E Q27008423-D1CD1539-E9F8-496F-BA2A-3E7878586F48 Q27026329-BEEB8743-AABE-425E-8D66-251C5B86914E Q27026484-FFEAE2C9-3310-41F0-9CA4-77E2FEA95305 Q27319571-C6A34EDE-6E77-46A2-898A-BCF78553C37B Q28080312-0BCDF8CE-38F8-4D67-87B9-EDEF4A51CF7E Q28081699-B18D16FB-BCD3-450F-ADE7-0F81FE7E0CDA Q30303138-BD823AD9-878B-4426-A4D8-08191A436306 Q33632100-1178292F-5D2E-47D1-A221-ABE48D32C9E3 Q33807771-EAC9D7AD-E8E5-4425-A5C0-443D7DEBD533 Q34115960-F5186D67-5B6A-4E34-962A-C6F6E3D2CD7A Q34383054-505C7688-91E7-4164-BD91-5D06A35D9F71 Q34624124-23C9ADF1-BC83-4AC3-AD28-AD6288C6559C Q34789569-36542FF1-EEAC-4AF6-A17F-0CE701BE52B5 Q35533181-93BCEAC8-5488-4060-A8FE-22E9872205F9 Q35724710-9C2A85A3-9BAD-4CA5-992C-867AA4945375 Q35980893-1B9BFA4F-B617-4EDF-BA12-8925A3C37797 Q36028047-5D879E0E-2BDE-4C68-90EF-758804574E5F Q36544867-7CF58443-50E7-4E78-92E2-9261A526DDCD Q36558375-F82E9CE9-AD35-4F7D-AB97-D77087D61DEE Q37072024-67668EBB-F7C7-4E0C-975F-5449335B37C5 Q37107843-C518FA61-7355-4A15-A61E-51218D608EA3 Q37370230-5D60C698-20CF-45DD-AAEC-C83427040D07 Q37614812-3516095D-88C2-4253-8C4A-7FE43C903E26 Q37658246-2E2BBD2B-22EA-4CDC-BDEC-D73FB4BDCFB5 Q37706835-9AD5580F-90E9-4016-BEF9-7642BCAC57C0 Q38117139-E7494DC5-A84C-438C-94E5-5E38487C5513 Q38180319-7E2B652D-7C22-484F-8EBB-E52823B2048A Q38218786-A6664F96-5335-48C1-95C9-FEBA2A0AE94F Q38335303-9BF9FCE2-3A0C-4682-8F7F-9003701A515E Q38482206-D082E6A4-C88C-4E2F-A39E-E52423E6B5C2 Q38687375-AF7DE72A-AA60-4023-B163-39C2690E2FA3 Q38766349-C000C4CD-F853-4E81-BED8-DF6422A52584 Q38869740-CFE18046-CDB1-4553-9C38-A1A80660F5B6 Q39003786-2AE2EDB0-1FC3-4391-AA67-FAC6958C6BAA Q39045535-20E63A20-6478-4F6F-9CF8-8ED2EA3BFD2C Q39130457-42D6575E-DACF-4D94-82CA-9ABDA674EAAB Q39978090-DB1C7DAC-6A6C-4D24-9D8D-6F18468E752D

P2860

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

http://www.wikidata.org/entity/Q36799229

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

T-cell receptor affinity and a ...... munity in T-cell immunotherapy

@en

type

label

T-cell receptor affinity and a ...... munity in T-cell immunotherapy

@en

prefLabel

T-cell receptor affinity and a ...... munity in T-cell immunotherapy

@en

P1433

Q36799229-E9F02DA4-C2D2-46CF-B261-47FC65FBDA50

P1476

Q36799229-54CB2561-9A01-4AB8-9E38-612149CA0045

P2093

Q36799229-03A34405-54D4-4D40-AF87-9DDEFA8B8C31

Q36799229-191D1134-B445-4A18-B434-970797EF0622

Q36799229-1A8A6A66-89CE-4612-AEDD-2302FE789FEB

Q36799229-23DB0BC3-6E0A-4236-9BA8-AC26582FC5CA

Q36799229-39543EE5-2655-4AB6-BE6D-222435C0BAC8

Q36799229-505626F6-E8F1-411E-A806-955CA63597A9

Q36799229-51703064-A7CF-46DC-B98A-20657143A7BD

Q36799229-895C2E79-AC2E-4102-BC36-15364E915650

Q36799229-8DE95312-3B9E-4324-A84E-CCA9B473A77A

Q36799229-B57681EC-A040-4B5F-9226-E8979E9E8841

P2860

Q36799229-0069A50D-A1C2-4889-840F-2C6E87266B36

Q36799229-041B4F8E-9D10-4F0A-BD41-E5EF095495EE

Q36799229-07538C6E-8268-4636-ACC6-DE490DDD829D

Q36799229-077B0049-7AE5-494C-AB1D-CD4D8D8909F8

Q36799229-078CA359-681E-47C2-BFA6-5FFD6064FACF

Q36799229-13621463-3846-4D1E-98FF-9B90205A0CF9

Q36799229-137D29E3-6049-4DB2-A217-4FF206F9CAC5

Q36799229-19314AEF-E660-4A88-96A2-A0D77D6E9355

Q36799229-1B0718D5-F529-4994-95DA-81D3896476EF

Q36799229-1D3EBEF0-986B-4ECB-921E-D4A5F84276EC

P304

Q36799229-88441081-22CE-40B0-AA77-A8A96CB13AD8

P31

Q36799229-5EF53B08-EAB7-48FA-94EA-31CC28E17120

P356

Q36799229-0FCE92C7-2CFA-4F9A-910D-F26B1DBE33D0

P407

Q36799229-F51C2FC2-50B9-4D15-9460-EEF540CE4CD9

P433

Q36799229-08C2CC50-04BD-4E00-B8AD-28B26C05D166

P478

Q36799229-F3CFDE20-3364-42F9-B6B7-AE4206063831

P50

Q36799229-50A53D51-2D85-4A92-93E1-F5CB4F1B11FA

P577

Q36799229-49750058-91B0-4B0B-8A62-169220A3EABC

P5875

Q36799229-8F09621B-41BB-4736-AEC9-C5D4566174F3

P698

Q36799229-B2A81D21-3821-453B-BC7A-09B9957602FF

P921

Q36799229-8C4824FC-7B75-4E70-8EA7-7950458F5D25

P932

Q36799229-85A376FC-8148-4426-9F14-5AE6A865FF3B

P356

PNAS.1221609110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

T-cell receptor affinity and a ...... munity in T-cell immunotherapy

@en

P2093

Eleazar Vega-Saenz de Miera

http://www.w3.org/2001/XMLSchema#string

Emily Corse

http://www.w3.org/2001/XMLSchema#string

Farbod Darvishian

http://www.w3.org/2001/XMLSchema#string

Iman Osman

http://www.w3.org/2001/XMLSchema#string

Josh Boyer

http://www.w3.org/2001/XMLSchema#string

Karolina Malecek

http://www.w3.org/2001/XMLSchema#string

Katelyn McGary

http://www.w3.org/2001/XMLSchema#string

Kevin Huang

http://www.w3.org/2001/XMLSchema#string

Laura A Johnson

http://www.w3.org/2001/XMLSchema#string

Michelle Krogsgaard

http://www.w3.org/2001/XMLSchema#string

P2860

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

Cancer regression in patients after transfer of genetically engineered lymphocytes

T cell activation

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation

TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms

Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination

P304

6973-6978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1221609110

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236193300

http://www.w3.org/2001/XMLSchema#string

P698

23576742

http://www.w3.org/2001/XMLSchema#string

P921

P932

3637771

http://www.w3.org/2001/XMLSchema#string